IRF4
MIM.601900 HGNC:6119 6p25-p23
Rearrangements
IRF4 (interferon regulatory factor-4) translocations have been observed in cutaneous anaplastic large cell lymphomas.
Expression in tumors
MUM1 expression in 35% of mantle cell lymphoma (MCL)
- Mantle cell lymphoma (MCL) characteristically express CD20, CD5, and cyclin-D1, carries the translocation t(11;14) (q13;q32) and typically has no expression of germinal center cell markers. So-called aberrant phenotypes such as CD5 negative and cyclin-D1-negative MCL have been described. Also few cases with CD10 and/or BCL-6 protein expression have been reported.
There is a clinical utility of FISH for IRF4 in the differential diagnosis of T-cell lymphoproliferative disorders in skin biopsies, with detection of a translocation favoring cutaneous anaplastic large cell lymphoma.
Like all FISH studies, IRF4 testing must be interpreted in the context of morphology, phenotype, and clinical features.
References
Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Wada DA, Law ME, Hsi ED, Dicaudo DJ, Ma L, Lim MS, Souza AD, Comfere NI, Weenig RH, Macon WR, Erickson LA, Ozsan N, Ansell SM, Dogan A, Feldman AL. Mod Pathol. 2010 Dec 17. PMID: #21169992# [Free]
BCL6, MUM1, and CD10 Expression in Mantle Cell Lymphoma. Gualco G, Weiss LM, Harrington WJ Jr, Bacchi CE. Appl Immunohistochem Mol Morphol. 2009 Oct 12. PMID: #19826251#